Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 22, 2020

Daiichi Sankyo begins oncology therapy trial for metastatic tumours

Daiichi Sankyo has dosed the first patient in a first-in-human global Phase I trial to evaluate a Glycoprotein-A Repetitions Predominant (GARP) directed immuno-oncology therapy, DS-1055, in patients with advanced or metastatic solid tumours.

Daiichi Sankyo has dosed the first patient in a first-in-human global Phase I trial to evaluate a Glycoprotein-A Repetitions Predominant (GARP) directed immuno-oncology therapy, DS-1055, in patients with advanced or metastatic solid tumours.

DS-1055 is a monoclonal antibody that can target GARP, a transmembrane protein seen on the surface of activated Tregs in the tumour microenvironment.

The therapy can potentially aid GARP positive Tregs to promote anti-tumour immunity.

At present, no GARP directed therapies have been approved for cancer treatment.

Daiichi Sankyo Global Oncology Development, Alpha Portfolio vice-president Arnaud Lesegretain said: “We are pleased to initiate clinical development to further evaluate the novel mechanism behind DS-1055, which was specifically designed to decrease the number of GARP expressing regulatory T cells and restore antitumor immune response.

“Evidence suggests that DS-1055 could serve as a new type of immune-based therapy for patients with various cancers, including those resistant or refractory to checkpoint inhibitors.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The global, multi-centre, open-label dose escalation trial will analyse the safety, tolerability and preliminary efficacy of DS-1055 in adult patients with relapsed/refractory advanced or metastatic head and neck, gastric and esophageal cancers and other tumour types.

Those who have progressed on standard treatments, including checkpoint inhibitors, will be part of the trial.

Around 40 participants will be enrolled in the US and Japan for the trial that will determine the maximum tolerated dose and recommended dose of DS-1055 for conducting further studies.

The safety endpoints of the trial will include analysis of dose-limiting toxicities and adverse events.

Efficacy endpoints of the trial will be objective response rate, disease control rate, duration of response, time to response, progression-free survival and overall survival.

The study will also evaluate pharmacokinetic, immunogenicity, and biomarker endpoints.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU